20 results
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
their future with their respective companies. These uncertainties may impair Pyxis Oncology’s and Apexigen’s ability to retain, recruit or motivate key … be detrimental to Apexigen if Apexigen cannot recruit suitable replacements in a timely manner. The competition for qualified personnel
S-4/A
lioxc1r2zszv h7123
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
r6dlu ecuzos
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
10-K
lhbzwk0u0ed
29 Mar 22
Annual report
7:36am
10-Q
1pt4r796wsb4bp5
15 Nov 21
Quarterly report
7:54am
424B4
cd6bbhiuioaorcwn
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1
ohiccy6yr1i6vvpiyz31
17 Sep 21
IPO registration
5:00pm
DRS/A
97f5f
10 Sep 21
Draft registration statement (amended)
12:00am
DRS/A
4u6if wtrv3rlgui
4 Aug 21
Draft registration statement (amended)
12:00am
DRS
j1smuh7y
21 Jun 21
Draft registration statement
12:00am
- Prev
- 1
- Next